title: [Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer.
  
  
  METHODS
  Between October 2001 and October 2006, we retrospectively studied 49 FDG-PET performed in 40 women (age: 52.4 +/- 12.2 years) with ovarian cancer, who had suspicion of recurrent disease by positive morphologic imaging tests (MIT) or increased tumour markers and negative MIT. All patients underwent whole body FDG-PET after the injection of 370-434 MBq of (18)FDG. The results were confirmed by histology in 31 cases, and by clinical-radiological follow-up in 18.
  
  
  RESULTS
  Prevalence of disease was 79.6 %. We obtained a global sensitivity and positive predictive value of 87.2 % and 87.2 %, and an accuracy of 79.6 %. Results led to a change in the patient's management in 25 cases (51 %). Subgroup results were: Sensitivity of 81.8 % in patients with increased tumour markers and negative MIT, and 89.3 % in patients with operable malignant lesions.
  
  
  CONCLUSIONS
  FDG-PET has high sensitivity and clinical impact in patients with suspicion of recurrent ovarian cancer. Better results were obtained in patients with increased tumour markers and negative MIT.
authors.affiliation: Unidad Diagnóstica de Gestión de Medicina Nuclear, Hospitales Universitarios Virgen del Rocío, Sevilla, España. nacho_cuenca@hotmail.com
authors.forename: J I
authors.initials: JI
authors.lastname: Cuenca Cuenca
authors.forename: I
authors.initials: I
authors.lastname: Borrego Dorado
authors.forename: R
authors.initials: R
authors.lastname: Vázquez Albertino
authors.forename: P
authors.initials: P
authors.lastname: Gómez Camarero
authors.forename: S
authors.initials: S
authors.lastname: Sanz Viedma
authors.forename: R
authors.initials: R
authors.lastname: Fernández López
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002277:Carcinoma / Q000097:blood / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000628:therapy; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D015995:Prevalence; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013030:Spain / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18